195 related articles for article (PubMed ID: 38294187)
1. Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF.
Capone F; Nambiar N; Schiattarella GG
Curr Opin Cardiol; 2024 May; 39(3):148-153. PubMed ID: 38294187
[TBL] [Abstract][Full Text] [Related]
2. Obesity pharmacotherapy: incretin action in the central nervous system.
Boer GA; Hay DL; Tups A
Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
[TBL] [Abstract][Full Text] [Related]
3. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
4. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
5. Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.
Cimino G; Vaduganathan M; Lombardi CM; Pagnesi M; Vizzardi E; Tomasoni D; Adamo M; Metra M; Inciardi RM
ESC Heart Fail; 2024 Apr; 11(2):649-661. PubMed ID: 38093506
[TBL] [Abstract][Full Text] [Related]
6. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
[TBL] [Abstract][Full Text] [Related]
7. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
8. Targeting obesity for therapeutic intervention in heart failure patients.
Sato R; von Haehling S
Expert Rev Cardiovasc Ther; 2024 Jun; 22(6):217-230. PubMed ID: 38864827
[TBL] [Abstract][Full Text] [Related]
9. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Christensen L; Davies M; Hovingh KG; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Petrie MC
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1000-1010. PubMed ID: 37294245
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in peptide-based therapies for obesity and type 2 diabetes.
Bailey CJ; Flatt PR; Conlon JM
Peptides; 2024 Mar; 173():171149. PubMed ID: 38184193
[TBL] [Abstract][Full Text] [Related]
11. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
12. Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
Harrington J; Felker GM; Januzzi JL; Lam CSP; Lingvay I; Pagidipati NJ; Sattar N; Van Spall HGC; Verma S; McGuire DK
Curr Cardiol Rep; 2024 Mar; 26(3):61-71. PubMed ID: 38551786
[TBL] [Abstract][Full Text] [Related]
13. New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review.
Jalil JE; Gabrielli L; Ocaranza MP; MacNab P; Fernández R; Grassi B; Jofré P; Verdejo H; Acevedo M; Cordova S; Sanhueza L; Greig D
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673991
[TBL] [Abstract][Full Text] [Related]
14. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
[TBL] [Abstract][Full Text] [Related]
15. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
16. An update on peptide-based therapies for type 2 diabetes and obesity.
Bailey CJ; Flatt PR; Conlon JM
Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818
[TBL] [Abstract][Full Text] [Related]
17. Incretin therapy for diabetes mellitus type 2.
Holst JJ
Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):2-10. PubMed ID: 31815785
[TBL] [Abstract][Full Text] [Related]
18. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
Belli M; Barone L; Bellia A; Sergi D; Lecis D; Prandi FR; Milite M; Galluccio C; Muscoli S; Romeo F; Barillà F
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
